Markets:

Overview

News

Currencies

International

Treasuries

Wesana Health Hldgs Inc (OP:WSNAF)

0.0163 +0.0108 (+196.36%)

Streaming Delayed Price Updated: 12:44 PM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Wesana Health Hldgs Inc

Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More ↗

July 11, 2023

First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic...

Via Benzinga

Wesana Shareholders Vote For Psilocybin And CBD Therapy Asset Sales To Lucy Scientific ↗

June 12, 2023

Psychedelics drug developer Wesana Health Holdings Inc. (OTCQB: WSNAF) announced all matters discussed at the company’s annual general and special shareholders meeting of June 9 were approved by a...

Via Benzinga

Disney, Amgen, First Republic, Psychedelics: How One CEO's Universal Deal-Making Approach Shapes Industries ↗

June 05, 2023

In the dynamic world of business, adaptability is king, a principle veteran executive Richard Nanula has embodied throughout his career. "Every place I've been... maybe you could conclude that they...

Via Benzinga

EXCLUSIVE: Infrastructure Built For Healing: 'Consolidation And Legitimacy Are Crucial For Psychedelic Industry Growth' ↗

April 13, 2023

“Investing in real estate can help expand experiential medicines like ketamine and MDMA for treating PTSD and build infrastructure for upcoming FDA-approved therapies,” said Daniel Carcillo, founder...

Via Benzinga

What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry ↗

April 03, 2023

The world of psychedelics is evolving rapidly, and the Benzinga Psychedelics Capital Conference is the premier event for those who want to be part of this exciting journey.

Via Benzinga

High-Profile Highs: How Celebrity Advocacy Is Transforming Society's Views On Psychedelics And Cannabis ↗

March 29, 2023

As part of the recent so-called “psychedelics renaissance,” numerous celebrities, global

Via Benzinga

Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More ↗

March 27, 2023

Australia: Enveric, FSD Pharma, Psyence & Others Advance Businesses

Via Benzinga

Lucy Scientific Shares Trading Higher On Asset Purchase Agreement Of Psychedelic Assets From Wesana Health ↗

March 21, 2023

Lucy Scientific Discovery Inc. (NASDAQ: LSDI) has entered into a definitive asset purchase agreement with Wesana Health Holdings Inc. (OTCQB: WSNAF).

Via Benzinga

NGOs Raise Money To Help Stem Opioid Addiction With Psychedelics Program ↗

October 19, 2022

The 100 Million Ways Foundation (100MW), a not-for-profit organization focused on harm reduction and improving quality of life of those with opioid use disorders, pulled in nearly $100,000 in...

Via Benzinga

Wesana Sells Clinic Management Services Organization To Strengthen Assets ↗

September 02, 2022

Life sciences company Wesana Health (OTCQB: WSNAF) has completed the sale of its indirect, wholly-owned subsidiary Advanced Psychiatric Management LLC for a total of $2,100,000.

Via Benzinga

4 Psychedelics Companies Post Financial Results: Learn How Field Trip, Wesana, Braxia and Irwin Naturals Performed ↗

August 30, 2022

Field Trip (NASDAQ: FTRP), Wesana (OTCQB: WSNAF), Braxia (OTC: BRAXF) and

Via Benzinga

Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved ↗

April 25, 2022

Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami...

Via Benzinga

Missed The Benzinga Psychedelics Capital Conference? Check Out Full Recording And Exclusive Coverage ↗

April 25, 2022

Via Benzinga

Daniel Carcillo Explains How Wesana Health Is Using Psychedelics To Treat Traumatic Brain Injury ↗

April 20, 2022

Daniel Carcillo is co-founder and CEO of Wesana Health (OTC: WSNAF), a data-driven life sciences company pioneering clinical therapies and drug development through the FDA pathway.

Via Benzinga

EXCLUSIVE: Catalysts To Watch For In The Psychedelic Space ↗

April 19, 2022

Any biotech investor knows how important catalysts are for the companies in the space. One FDA approval or denial can make or break the price of the stock. In the psychedelic space, catalysts could be...

Via Benzinga

Wesana Health One Step Closer To Clinical Trials Of Psilocybin And CBD Based Treatment Of Brain Injury Related MDD ↗

March 14, 2022

Wesana Health Holdings Inc. (OTCQB: WSNAF) (CSE:WESA) have received a full written response from the Food and Drug ...

Via Benzinga

Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS ↗

January 18, 2022

New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:

Via Benzinga

Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana ↗

January 11, 2022

On Tuesday, three public companies in the psychedelics/biotech space announced significant milestones in their drug development pipelines.

Via Benzinga

The Legacy Of Dr. Aaron Beck, Father Of Cognitive Therapy, Lives On In Psychedelic Medicine ↗

November 04, 2021

Dr. Aaron T. Beck, the father of cognitive therapy, died on Monday at his home in Philadelphia at age 100. Beck&rsq...

Via Benzinga

Topics Death

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation ↗

October 18, 2021

The Week In Psychedelics

Via Benzinga

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are ↗

October 13, 2021

Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...

Via Benzinga

Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial ↗

September 20, 2021

AdvisorShares Launches First NYSE-listed Actively-managed Psychedelics ETF On Thursday, AdvisorShares

Via Benzinga

Can MDMA Treat Traumatic Brain Injury? $1.5 Million Are Being Committed To Finding Out ↗

September 14, 2021

Wesana Health (CSE:WESA) (OTCQB:

Via Benzinga

Psyched: Atai Launches 'Salvia Divinorum' Subsidiary, Mindset, Psilera and Wesana's Preclinical Trials, Origin Raises $5M ↗

August 16, 2021

Atai Life Sciences Launches New Salvia Divinorum Subsidiary Atai Life Sciences (NASDAQ:

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.